샘플 요청 목록

 카트 문의
시장보고서
상품코드
1576946

안지오 스위트(Angio Suites) : 시장 인사이트, 경쟁 구도, 시장 예측(-2030년)

Angio Suites - Market Insights, Competitive Landscape, and Market Forecast - 2030
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 안지오 스위트(Angio Suites) 시장 규모는 2023년에 21억 8,000만 달러여, 2030년까지 30억 5,000만 달러에 달할 것으로 예측되며, 2024-2030년의 예측 기간에 CAGR로 5.75%의 성장이 전망됩니다. 시장은 주로 심방세동, 말초동맥 질환(PAD), 관상동맥 질환(CAD) 등의 심혈관질환과 같은 만성질환 환자 증가, 주요 기업의 혁신적인 제품 개발 활동, 노령 인구 증가로 인해 상당한 시장 성장을 보이고 있으며, 이는 2024-2030년의 예측 기간 중 안지오 스위트 시장 전체 성장을 가속화할 것으로 예상됩니다.

Angiosuite 시장 역학

World Heart Report(2023년)의 자료에 따르면 2021년 전 세계에서 5억 명 이상의 사람들이 심혈관 질환을 앓고 있습니다. 또한 미국심장협회(American Heart Association, 2023년)의 최근 자료에 따르면 2030년까지 전 세계에서 1,200만 명 이상이 심방세동으로 고통받을 것으로 추정됩니다.

British Heart Foundation, Global Heart & Circulatory Diseases Factsheet(2024)에 따르면 전 세계에서 약 2억 명이 CAD를 앓고 있습니다.

American Heart Association(2023년) 자료에 따르면 전 세계 평균 약 2억 명이 PAD를 앓고 있습니다. 또한 Global Burden of Disease(2019)에 따르면 2019년 전 세계 40-70세 PAD 유병자 수는 5,640만 명으로 집계되었습니다.

Angio Suite는 CAD, PAD, 심방세동과 같은 심혈관 질환의 진단 및 치료에 필수적입니다. 또한 Angio Suite는 정상적인 심장 박동 리듬을 회복하는 심방세동 절제술과 같은 카테터 기반 시술에 사용할 수 있습니다.

안지오 스위트시장의 성장을 이끄는 또 다른 주요 요인은 안지오 스위트시장의 안전성과 정확성을 높이기 위한 제품 설계를 위한 끊임없는 기술 개발이 이루어지고 있다는 점입니다. 예를 들어 2021년 10월 인도 쉔다라바드에 위치한 야쇼다 병원(Yashoda Hospitals)은 뇌졸중, 심장마비 등 신경계 급성 질환에 대한 신속하고 진보된 치료를 제공하기 위해 DTAS(Direct to Angio Suite) 기술을 탑재한 'Bi-Plane Neuro Angio Procedure Suite'를 출시했습니다.

전 세계 규제기관의 제품 개발 활동이 활발해짐에 따라 앙기오스 제품군 시장도 성장할 것으로 예상됩니다. 예를 들어 2022년 5월 Philips는 새로운 MR 7700 3.0T MR 시스템에 대한 FDA 510(k) 승인을 발표했습니다.

따라서 위의 모든 요인들이 종합적으로 전체 안지오 스위트시장의 성장을 가속할 것입니다.

그러나 감염, 혈종, 혈관 손상 등의 부작용, 숙련된 인력 및 의료 인프라 부족 등은 안지오 스위트시장의 성장에 걸림돌이 될 수 있습니다.

안지오 스위트 시장 부문 분석

안지오 스위트 시장의 용도 중 스텐트 삽입술 부문이 2023년 가장 큰 매출 점유율을 차지할 것으로 예측됩니다. 이는 전 세계에서 뇌졸중으로 인한 스텐트 삽입술의 필요성이 증가하고 있으며, 뇌졸중 유병률이 전 세계에서 증가하여 장애 및 사망과 같은 심각한 결과를 초래하고 있기 때문인 것으로 추정되며, 안지오 스위트 시장의 이 부문은 상당한 매출을 창출할 것으로 예상됩니다.

또한 웨어러블 혈관조영제 개발에서 이루어지고 있는 기술 발전과 제품 혁신은 혈관조영제 시장의 성장을 가속할 가능성이 높습니다. 예를 들어 2022년 6월 지멘스 헬시니어스(Siemens Healthineers)는 스텐트 삽입술, 뇌졸중 진단 및 치료 등 다양한 용도의 혈관조영 시스템인 Artis Icono를 출시했습니다. 이 시스템은 원활한 통합 및 타사 인터페이스를 갖춘 2D 및 3D 이미징을위한 새로운 시스템 메커니즘과 이미지 체인을 통해 구현됩니다.

세계의 안지오 스위트 시장에 대해 조사분석했으며, 각 지역의 시장 규모와 예측, 과거 3년 제품/기술개발, 시장의 주요 기업, 향후 기회등의 정보를 제공하고 있습니다.

목차

제1장 안지오 스위트 시장 보고서 서론

제2장 안지오 스위트 시장의 개요

  • 시장의 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 안지오 스위트 시장의 주요 요인 분석

  • 안지오 스위트 시장 촉진요인
  • 안지오 스위트 시장 억제요인과 과제
  • 안지오 스위트 시장의 기회

제6장 안지오 스위트 시장의 Porter's Five Forces 분석

제7장 안지오 스위트 시장 평가

  • 유형별
    • 싱글 프레인
    • 바이프레인
  • 용도별
    • 혈관조영
    • 혈관성형술
    • 스텐트 유치술
    • 바이패스 수술
    • 기타
  • 지역
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 안지오 스위트 시장의 기업과 제품의 개요

  • Siemens Healthineers
  • Koninklijke Philips N.V
  • Lam Vascular and Associates
  • Hitachi, Ltd.
  • ESAOTE SPA
  • IMRIS
  • Onex Corporation
  • Canon Inc.
  • 3D Systems, Inc.
  • GE HealthCare
  • Shimadzu Corporation
  • GIMIAS
  • FUJIFILM Holdings Corporation
  • Hologic, Inc.
  • Planmeca
  • Mindray Medical International Limited
  • ZEISS International
  • Guerbet
  • Surgical Science
  • B.Braun Melsungen AG

제9장 KOL의 견해

제10장 프로젝트 어프로치

제11장 DelveInsight 소개

제12장 면책사항, 문의

KSA 24.10.31

Angio Suites Market by Type (Single-Plane and Bi-Plane), Application (Angiography, Angioplasty, Stenting, Bypass Surgery, and Others), and Geography (North-America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing cases of chronic disorders and the rising product developmental activities worldwide

The angio suites market was valued at USD 2.18 billion in 2023, growing at a CAGR of 5.75% during the forecast period from 2024 to 2030 to reach USD 3.05 billion by 2030. The angio suites market is observing substantial market growth primarily owing to the increasing cases of chronic disorders such as cardiovascular diseases including atrial fibrillation, peripheral artery disease (PAD), and coronary artery disease (CAD), innovative product developmental activities by leading companies, and the rising geriatric population that are expected to escalate the overall growth of the angio suites market during the forecast period from 2024 to 2030.

Angio Suites Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021 it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to recent data provided by the American Heart Association (2023), it is estimated that by 2030 over 12 million people will have atrial fibrillation globally.

According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are living with CAD around the world.

As per data by the American Heart Association (2023), around 200 million live with PAD globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.

Angio suites are vital for diagnosing and treating cardiovascular diseases like CAD, PAD, and atrial fibrillation. Moreover, angio suites can be used for catheter-based procedures like atrial fibrillation ablation to restore normal heart rhythm.

Another prominent factor responsible for the growth of the angio suites market is the constant technological developments taking place in the angio suites market for product design, and for increasing its safety and precision. For instance, in October 2021, Yashoda Hospitals, located in Secunderabad, India launched a 'Bi-Plane Neuro Angio Procedure Suite' with DTAS (Direct to Angio Suite) technology used for providing quick and highly advanced treatment in cases of brain stroke and neurological emergencies such as heart attacks.

Increased product developmental activities by regulatory bodies worldwide is also slated to witness market growth for angio suites. For example in May 2022, Philips announced FDA 510(k) clearance for its new MR 7700 3.0T MR system, giving high performance and precision for both research and advanced clinical diagnostics.

Therefore, all the factors stated above collectively will drive the overall angio suites market growth.

However, side effects such as infections, hematoma, vessel injuries, lack of skilled workforce and medical infrastructure, and others may prove to be challenging factors for the angio suites market growth.

Angio Suites Market Segment Analysis:

Angio Suites Market by Type (Single-Plane and Bi-Plane), Application (Angiography, Angioplasty, Stenting, Bypass Surgery, and Others), and Geography (North-America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of angio suites market, the stenting category is expected to have a significant revenue share in the year 2023. This can be ascribed to an increase in stenting procedures around the world, required in acute cases of stroke, rising prevalence of stroke cases globally, leading to serious consequences like disability and death, this segment of the angio suites market is expected to generate considerable revenue.

Furthermore, technological advancements and product innovations taking place in the development of wearable angio suites are likely to propel the angio suites market growth. For instance, in June 2022, Siemens Healthineers, launched the Angiography System Artis Icono, for various applications like stenting, stroke diagnosis and treatment and others. It is enabled with new system mechanics and image chains for 2D and 3D imaging with seamless integration and a third-party interface.

Angio suites designed for stenting procedures feature advanced imaging technologies, specialized catheterization tools, and patient monitoring systems. They are primarily used to treat CAD and PAD by placing stents to keep narrowed or blocked arteries open, thus improving blood flow and reducing the risk of heart attacks. These suites also facilitate emergency interventions for acute coronary syndromes, ensuring timely cardiovascular care.

Therefore, the widespread uses and various key features offered by stenting category, that enhance performance and usability are solidifying the impact on the growth of the overall angio suites market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall angio suites market:

Among all the regions, North America is expected to dominate the angio suites market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high prevalence of CAD and other heart conditions, along with associated risk factors for cardiovascular disorders, combined with significant advancements in product development and regulatory approvals that are acting as key factors contributing to the growth of the angio suites market in the North America region during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure among others.

Data from the Canadian Institute for Health Information (2024), stated that in 2022, 2.4 million Canadians were affected by heart disease. Also, according to the American Health Association (2022), Canada stands the second most to be affected by stroke globally in the year 2021.

Angio suites enable crucial diagnostic procedures like angiography to visualize coronary arteries and identify blockages. For myocardial infarction, angio suites facilitate interventions such as angioplasty and stenting to restore blood flow to the heart. Their versatility also allows for the treatment of various heart conditions, ensuring timely diagnosis and effective care.

Rising product developmental activities by regulatory bodies in the region will further boost the market for angio suites. For example, in March 2022, Philips received 510(k) market clearance from the U.S. Food & Drug Administration (FDA) for its angio suite Philips Capsule Surveillance solution, paving the way for widespread deployment across healthcare systems in the US. The angio suite is capable of utilizing streaming data from virtually any connected medical device and helps in the analysis to generate actionable insights and alerts.

Additionally, in June 2022, Canon Medical Systems decided to collaborate with The Harley Street Healthcare Group Canada to launch a group of innovative diagnostic centers across Ontario. The diagnostic center is said to possess a highly equipped Angiography suite with the latest X-ray generators, Molecular Imaging, Ultrasound, and Healthcare Informatics.

Therefore, the presence of a large patient population base with heart disorders, coupled with a rise in regulatory approvals for angio suites is expected to bolster the growth of the angio suites market in the North American region during the forecast period.

Angio Suites Market key players:

Some of the key market players operating in the angio suites market include Siemens Healthineers, Koninklijke Philips N.V, Lam Vascular and Associates, Hitachi, Ltd., ESAOTE SPA, IMRIS, Onex Corporation, Canon Inc., 3D Systems, Inc., GE HealthCare, Shimadzu Corporation, GIMIAS, FUJIFILM Holdings Corporation, Hologic, Inc., Planmeca, Mindray Medical International Limited, ZEISS International, Guerbet, Surgical Science, B.Braun Melsungen AG, and others.

Recent Developmental Activities in the Angio Suites Market:

  • In June 2022, Siemens Healthineers, launched the Angiography System Artis Icono, for precise tumor embolization. It is enabled with new system mechanics and image chains for 2D and 3D imaging with seamless integration and a third-party interface.
  • In December 2021, GE Healthcare, an auxiliary company of well-known Massachusetts, United States-based company "General Electric" announced the successful acquisition of Boston, United States-based imaging company "BK Medical".

Key Takeaways from the Angio Suites Market Report Study

  • Market size analysis for current angio suites market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the angio suites market.
  • Various opportunities available for the other competitors in the angio suites market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current angio suites market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for automated external defibrillator market growth in the coming future?

Target Audience who can be benefited from this Angio Suites Market Report Study

  • Angio suites product providers
  • Research organizations and consulting companies
  • Angio suites-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in angio suites
  • Various end-users who want to know more about the angio suites market and the latest technological developments in the angio suites market.

Frequently Asked Questions for the Angio Suites Market:

1. What are angio suites?

  • The angio suite is an examination room where complex surgical procedures like angiography, stenting, bypass surgery, etc. are performed with high precision. It helps in the detection and observation of damaged blood vessels present in different organs, helping in the diagnosis and treatment of conditions like aneurysms, vascular stenosis, coronary atherosclerosis, etc.

2. What is the market for angio suites?

  • The angio suites market was valued at USD 2.18 billion in 2023, growing at a CAGR of 5.75% during the forecast period from 2024 to 2030 to reach USD 3.05 billion by 2030.

3. What are the drivers for the angio suites market?

  • The angio suites market is observing substantial market growth primarily owing to the increasing cases of chronic disorders such as cardiovascular diseases including atrial fibrillation, peripheral artery disease (PAD), and coronary artery disease (CAD), innovative product developmental activities by leading companies, and the rising geriatric population that are expected to escalate the overall growth of the angio suites market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the angio suites market?

  • Some of the key market players operating in the angio suites market include Siemens Healthineers, Koninklijke Philips N.V, Lam Vascular and Associates, Hitachi, Ltd., ESAOTE SPA, IMRIS, Onex Corporation, Canon Inc., 3D Systems, Inc., GE HealthCare, Shimadzu Corporation, GIMIAS, FUJIFILM Holdings Corporation, Hologic, Inc., Planmeca, Mindray Medical International Limited, ZEISS International, Guerbet, Surgical Science, B.Braun Melsungen AG, and others.

5. Which region has the highest share in the angio suites market?

North America is expected to dominate the overall angio suites market during the forecast period from 2024 to 2030. This can be attributed to several factors including the high prevalence of coronary artery disease and other heart conditions, along with associated risk factors for cardiovascular disorders, combined with significant advancements in product development and regulatory approvals that are acting as key factors contributing to the growth of the angio suites market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Angio Suites Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Angio Suites Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Angio Suites Market Key Factors Analysis

  • 5.1. Angio Suites Market Drivers
    • 5.1.1. Increasing cases of chronic disorders
    • 5.1.2. Rising product developmental activities
    • 5.1.3. Rising geriatric population
  • 5.2. Angio Suites Market Restraints and Challenges
    • 5.2.1. Side effects such as infections, hematoma, and vessel injuries
    • 5.2.2. Lack of skilled workforce and medical infrastructure
  • 5.3. Angio Suites Market Opportunities
    • 5.3.1. Integration of AI, robotics and automation
    • 5.3.2. Increasing regulatory and research opportunities

6. Angio Suites Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Angio Suites Market Assessment

  • 7.1. By Type
    • 7.1.1. Single-plane
    • 7.1.2. Bi-plane
  • 7.2. By Application
    • 7.2.1. Angiography
    • 7.2.2. Angioplasty
    • 7.2.3. Stenting
    • 7.2.4. Bypass Surgery
    • 7.2.5. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States Angio Suites Market Size in USD million (2021-2030)
      • 7.3.1.2. Canada Angio Suites Market Size in USD million (2021-2030)
      • 7.3.1.3. Mexico Angio Suites Market Size in USD million (2021-2030)
    • 7.3.2. Europe
      • 7.3.2.1. France Angio Suites Market Size in USD million (2021-2030)
      • 7.3.2.2. Germany Angio Suites Market Size in USD million (2021-2030)
      • 7.3.2.3. United Kingdom Angio Suites Market Size in USD million (2021-2030)
      • 7.3.2.4. Italy Angio Suites Market Size in USD million (2021-2030)
      • 7.3.2.5. Spain Angio Suites Market Size in USD million (2021-2030)
      • 7.3.2.6. Rest of Europe Angio Suites Market Size in USD million (2021-2030)
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China Angio Suites Market Size in USD million (2021-2030)
      • 7.3.3.2. Japan Angio Suites Market Size in USD million (2021-2030)
      • 7.3.3.3. India Angio Suites Market Size in USD million (2021-2030)
      • 7.3.3.4. Australia Angio Suites Market Size in USD million (2021-2030)
      • 7.3.3.5. South Korea Angio Suites Market Size in USD million (2021-2030)
      • 7.3.3.6. Rest of Asia-Pacific Angio Suites Market Size in USD million (2021-2030)
    • 7.3.4. Rest of the World (RoW)
      • 7.3.4.1. Middle East Angio Suites Market Size in USD million (2021-2030)
      • 7.3.4.2. Africa Angio Suites Market Size in USD million (2021-2030)
      • 7.3.4.3. South America Angio Suites Market Size in USD million (2021-2030)

8. Angio Suites Market Company and Product Profiles

  • 8.1. Siemens Healthineers
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Koninklijke Philips N.V
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Lam Vascular and Associates
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Hitachi, Ltd.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. ESAOTE SPA
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. IMRIS
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Onex Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Canon Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. 3D Systems, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. GE HealthCare
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Shimadzu Corporation
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. GIMIAS
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. FUJIFILM Holdings Corporation
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Hologic, Inc.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Planmeca
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Mindray Medical International Limited
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. ZEISS International
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Guerbet
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Surgical Science
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. B.Braun Melsungen AG
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제